THE KöP OXYCONTIN I SVERIGE DIARIES

These steps include things like course-broad basic safety labeling variations and new write-up-advertising and marketing prerequisites for all ER/LA opioid analgesics. FDA also responded to 2 citizen petitions concerning labeling of opioids. The meeting also furnished a chance to debate FDA’s initiatives to develop standardized in vitro testing